RxSight, Inc. (NASDAQ:RXST) Shares Acquired by No Street GP LP

No Street GP LP lifted its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 5.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 500,000 shares of the company's stock after purchasing an additional 25,000 shares during the quarter. RxSight comprises approximately 1.1% of No Street GP LP's investment portfolio, making the stock its 23rd biggest position. No Street GP LP owned 1.24% of RxSight worth $17,190,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of RXST. Barclays PLC grew its holdings in shares of RxSight by 389.8% during the 3rd quarter. Barclays PLC now owns 58,786 shares of the company's stock worth $2,906,000 after purchasing an additional 46,783 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of RxSight by 4.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,510 shares of the company's stock worth $9,516,000 after purchasing an additional 7,494 shares during the period. Harbor Investment Advisory LLC purchased a new position in shares of RxSight during the 4th quarter worth $52,000. KBC Group NV grew its holdings in shares of RxSight by 71.0% during the 4th quarter. KBC Group NV now owns 2,107 shares of the company's stock worth $72,000 after purchasing an additional 875 shares during the period. Finally, Van ECK Associates Corp lifted its stake in RxSight by 46.7% during the 4th quarter. Van ECK Associates Corp now owns 3,265 shares of the company's stock worth $112,000 after acquiring an additional 1,040 shares in the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

RxSight Stock Performance

RXST stock traded up $0.88 during mid-day trading on Friday, reaching $14.19. The company had a trading volume of 862,724 shares, compared to its average volume of 672,599. The company has a market capitalization of $576.64 million, a price-to-earnings ratio of -17.10 and a beta of 1.32. The firm has a fifty day simple moving average of $18.08 and a 200 day simple moving average of $30.25. RxSight, Inc. has a fifty-two week low of $12.53 and a fifty-two week high of $64.50.

RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.03). The company had revenue of $37.90 million for the quarter, compared to analyst estimates of $38.74 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. RxSight's revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) EPS. As a group, analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current year.

Insider Buying and Selling at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now owns 24,793 shares of the company's stock, valued at $637,428.03. This trade represents a 22.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.36% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on RXST. JPMorgan Chase & Co. reissued an "underweight" rating and set a $17.00 target price (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Bank of America reissued an "underperform" rating and set a $22.00 target price (down previously from $36.00) on shares of RxSight in a research note on Thursday, April 3rd. Wells Fargo & Company decreased their target price on RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 3rd. Piper Sandler began coverage on RxSight in a research note on Tuesday, April 15th. They set a "neutral" rating and a $18.00 target price on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $43.00 target price on shares of RxSight in a research note on Thursday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, RxSight has a consensus rating of "Hold" and a consensus target price of $37.60.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.